



ALEMBIC PHARMA

Pharmaceuticals

Earnings recovery on normalised Azithromycin base

- US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each
- EBITDA margin for Q3FY25 was 15.4% and we expect EBITDA margin to grow to 18.4% by FY27
- We maintain BUY and value the stock at 28x Dec'26 EPS due to healthy sales on normalised Azithromycin base for TP of Rs 1,032

Results below expectations due to decline in API sales: ALPM sales grew by 3.8% YoY (1.5% below our estimate), while EBITDA declined by 2.3% (8% below our estimate) and PAT by 24% (21% below our estimate) primarily due to higher tax rate. The decline in earnings was due to (1) lower API sales of 10% (23% lower than our estimate) due to price erosion, and (2) lower domestic sales of 3% (-1.5% below our estimate) due to higher Azithromycin base which offset 10% YoY growth in US and ROW markets.

Domestic sales to grow on normalised Azithromycin sales: India region sales was affected by higher base of Azithromycin sales reported during the Covid period and slower-than-expected recovery in the Cold and Cough segment resulting in 11% decline in the Acute therapy, offsetting 6% YoY and 22% YoY growth in the Specialty and Animal Health segments respectively. We expect the India region to grow by ~9% driven by (1) normalised base of Azithromycin in FY26E in the acute segment, (2) higher medical representative productivity, (3) uptick in well-diversified specialty and (4) continuous traction in the Animal Health segment.

US growth to continue driven by new product launches: During Q3, US grew by 10% YoY driven by easing price erosion pressure. During the period, ALPM launched two new products and expects to launch five new ones in Q4FY25. The company is focusing on injectables, peptides and complex therapies like Oncology and Ophthalmology within the new product segment. The company is shifting its products to F4 from F1 and expects new facility products to drive growth in coming quarters.

Valuations: As earnings were 20% lower than we estimated for Q3FY25, we cut our EPS estimates for FY25 by 17% to Rs 28.3, for FY26 by 20% to Rs 34.1 and for FY27 by 18% to Rs 45. However, due to normalized base of Azithromycin, healthy traction in the Animal Health and Specialised businesses, and strong non-oral solid portfolio in the US region we maintain our BUY rating and value the stock at 28x Dec'26 EPS to yield a TP of Rs 1,032 (Rs 1,412 earlier).

12 February 2025

Foram Parekh research@bobcaps.in

Key changes

	Target	Rating	
	•	<►	
Ticke	er/Price	ALPM IN/Rs 868	
Mark	et cap	US\$ 2.0bn	
Free	float	31%	
3M A	DV	US\$ 1.7mn	
52wk high/low		Rs 1,304/Rs 823	
Prom	noter/FPI/DII	70%/5%/13%	

Source: NSE | Price as of 11 Feb 2025

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E			
Total revenue (Rs mn)	62,290	65,616	72,954			
EBITDA (Rs mn)	9,337	9,867	11,825			
Adj. net profit (Rs mn)	6,172	5,565	6,698			
Adj. EPS (Rs)	31.4	28.3	34.1			
Consensus EPS (Rs)	31.4	36.7	44.6			
Adj. ROAE (%)	13.9	11.5	12.8			
Adj. P/E (x)	27.7	30.7	25.5			
EV/EBITDA (x)	19.0	17.8	14.6			
Adj. EPS growth (%)	80.2	(9.7)	20.4			
0 0 PL I DODOVDOD I						

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Fig 1 – Financial Highlight

Net Sales 16,927 16,306 3.8 16,480 2.7 49,025 47,18 4.0 62,290 65,616 72,954 Total Expenses 14,325 13,642 5.0 14,087 1.7 41,661 40,383 3.2 52,953 55,750 61,129 (%) of net sales 85 84 85 86 86 85 86 Raw material consumed 4,395 4,600 (4.6) 4.291 2.4 12,628 13,357 (5.5) 17,151 18,373 19,698 (%) of net sales 2.6 2.8 2.6 2.6 2.8 2.6 2.8 2.7 Staff cost 3,975 3,493 13.8 3,915 1.5 11,688 10,44 1.9 14,463 15,909 17,818 (%) of net sales 2.3 2.1 2.4 2.4 2.2 2.3 2.6 2.77 3.270 3.680 G%a A 4,600 4,397 4,583 6.73 4.702 <th>FY27E</th> <th>FY26E</th> <th>FY25E</th> <th>FY24</th> <th>YoY (%)</th> <th>9MFY24</th> <th>9MFY25</th> <th>QoQ (%)</th> <th>Q2FY25</th> <th>YoY (%)</th> <th>Q3FY24</th> <th>Q3FY25</th> <th>(Rs mn)</th>	FY27E	FY26E	FY25E	FY24	YoY (%)	9MFY24	9MFY25	QoQ (%)	Q2FY25	YoY (%)	Q3FY24	Q3FY25	(Rs mn)
(%) of net sales 85 84 85 85 86 85 85 84 Raw material consumed 4,395 4,608 (4.6) 4.291 2.4 12,628 13,357 (5.5) 17,151 18,373 19,698 (%) of net sales 26 28 26 26 28 28 28 27 Staff cost 3,975 3,493 13.8 3,915 1.5 11,688 10,444 11.9 14,463 15,909 17,818 (%) of net sales 23 21 24 24 22 23 24 24 SG&A 4,600 4,397 4.6 4,563 0.8 13,581 12,369 9.8 16,539 16,648 17,613 (%) of net sales 27 27 28 28 26 27 25 24 EBITDA 2,602 2,664 (2.3) 2,393 8.8 7,363 6,734 9.3 9,377 3,860 EBIT 1,902 1,969 (3.4) 1,668 12.7 5,267 4,702 </td <td>80,336</td> <td>72,954</td> <td>65,616</td> <td>62,290</td> <td>4.0</td> <td>47,118</td> <td>49,025</td> <td>2.7</td> <td>16,480</td> <td>3.8</td> <td>16,306</td> <td>16,927</td> <td>Net Sales</td>	80,336	72,954	65,616	62,290	4.0	47,118	49,025	2.7	16,480	3.8	16,306	16,927	Net Sales
Numerical consumed 4,395 4,608 (4,6) 4,291 2.4 12,628 13,357 (5.5) 17,151 18,373 19,698 (%) of net sales 2.6 2.8 2.6 2.6 2.8 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.8 2.8 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 2.5 2.4 2.6 2.7 3.6 2.7 3.6 3.6 7.63 6.734 9.3 9.337 9.6 1.1.8.5	65,556	61,129	55,750	52,953	3.2	40,383	41,661	1.7	14,087	5.0	13,642	14,325	Total Expenses
(%) of net sales262826282827Staff cost $3,975$ $3,493$ 13.8 $3,915$ 1.5 $11,688$ $10,444$ 11.9 $14,463$ $15,909$ $17,818$ (%) of net sales 23 21 24 24 22 23 24 22 23 24 SG&A $4,600$ $4,397$ 4.6 $4,563$ 0.8 $13,581$ $12,369$ 9.8 $16,639$ $16,468$ $17,613$ (%) of net sales 27 27 28 28 26 27 27 24 24 EBITDA $2,602$ $2,664$ (2.3) $2,393$ 8.8 $7,363$ $6,734$ 9.3 $9,37$ $9,867$ $11,825$ Depreciation 700 695 0.8 705 (0.7) $2,096$ $2,032$ $2,727$ $3,270$ $3,680$ EBIT $1,902$ $1,969$ (3.4) $16,88$ 12.7 $5,267$ $4,702$ 12.0 $6,611$ $6,597$ $8,146$ Interest 223 152 188 543 453 453 562 450 428 Other Income 95 29 167 283 247 11.4 $6,332$ $6,547$ $8,168$ Less: Minority Interest 401 41 273 899 114 $6,612$ $5,565$ $6,698$ Exceptional items 0 0 129 129 0 0 0 0 0 Reported PAT <td< td=""><td>82</td><td>84</td><td>85</td><td>85</td><td></td><td>86</td><td>85</td><td></td><td>85</td><td></td><td>84</td><td>85</td><td>(%) of net sales</td></td<>	82	84	85	85		86	85		85		84	85	(%) of net sales
Staff cost3,9753,49313.83,9151.511,68810,44411914,46315,90917,818(%) of net sales2321242422232424SG&A4,6004,3974.64,5630.813,58112,3699.816,53916,64817,613(%) of net sales272728282826272524EBITDA2,6022,664(2.3)2,3938.87,3636,7349.39,3379,86711,825Depreciation7006950.8705(0.7)2,0962,0322,7273,2703,680EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest2231521885434532452826428448Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Minority Interest(4)1(9)(11)610000Recurring PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Exceptional items00129129000016,55656,698	21,289	19,698	18,373	17,151	(5.5)	13,357	12,628	2.4	4,291	(4.6)	4,608	4,395	Raw material consumed
(%) of net sales2321242422232424SG&A4,6004,3974.64,5630.813,58112,3699.816,53916,64817,613(%) of net sales2727282826272524EBITDA2,6022,664(2.3)2,3938.87,3636,7349.39,3379,86711,825Depreciation7006950.8705(0.7)2,0962,0322,7273,2703,680EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest223152188543453562450428Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Taxation401412738991141609821,470Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,433(1.9)4,1214,377(5.9)6,1625,5656,698Exceptional items0012912900000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,	27	27	28	28		28	26		26		28	26	(%) of net sales
SG&A 4,600 4,397 4.6 4,663 0.8 13,581 12,369 9.8 16,539 16,468 17,613 (%) of net sales 27 27 28 28 26 27 25 24 EBITDA 2,602 2,664 (2.3) 2,393 8.8 7,363 6,734 9.3 9,367 9,867 11,825 Depreciation 700 695 0.8 705 (0.7) 2,096 2,032 2,727 3,270 3,680 EBIT 1,902 1,969 (3.4) 1,688 12.7 5,267 4,702 12.0 6,611 6,597 8,146 Interest 223 152 188 543 453 562 450 428 Other Income 95 29 167 283 247 283 400 450 PBT 1,774 1,846 (3.9) 1,667 6.4 5,008 4,497 11.4 6,332 6,547 <td>19,066</td> <td>17,818</td> <td>15,909</td> <td>14,463</td> <td>11.9</td> <td>10,444</td> <td>11,688</td> <td>1.5</td> <td>3,915</td> <td>13.8</td> <td>3,493</td> <td>3,975</td> <td>Staff cost</td>	19,066	17,818	15,909	14,463	11.9	10,444	11,688	1.5	3,915	13.8	3,493	3,975	Staff cost
(%) of net sales272728282826272524EBITDA2,6022,664(2.3)2,3938.87,3636,7349.39,3379,86711,825Depreciation7006950.8705(0.7)2,0962,0322,7273,2703,680EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest223152188543453562450428Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Taxation401412738991141609821,470Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Exceptional items0012912900001Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698EBITDA Margin74.071.722974.0774.271.725972.572.073.0BBITA Margin15.416.3<	24	24	24	23		22	24		24		21	23	(%) of net sales
EBITDA2,6022,664(2.3)2,3938.87,3636,7349.39,3379,86711,825Depreciation7006950.8705(0.7)2,0962,0322,7273,2703,680EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest223152188543453562450428Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Taxation401412738991146,3326,5478,168Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,403(19)4,1214,377(5.9)6,1625,5656,698Exceptional items0012912900000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.0I	19,201	17,613	16,468	16,539	9.8	12,369	13,581	0.8	4,563	4.6	4,397	4,600	SG&A
Depreciation7006950.8705(0.7)2,0962,0322,7273,2703,680EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest223152188543453562450428Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Taxation401412738991141609821,470Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,403(1.9)4,1214,377(5.9)6,1625,5656,698Exceptional items001291290001Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)153274.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	24	24	25	27		26	28		28		27	27	(%) of net sales
EBIT1,9021,969(3.4)1,68812.75,2674,70212.06,6116,5978,146Interest223152188543453562450428Other Income9529167283247283400450PBT1,7741,846(3.9)1,6676.45,0084,49711.46,3326,5478,168Less: Taxation401412738991141609821,470Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,403(1.9)4,1214,377(5.9)6,1625,5656,698Exceptional items0012912900000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)51572.073.074.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	14,780	11,825	9,867	9,337	9.3	6,734	7,363	8.8	2,393	(2.3)	2,664	2,602	EBITDA
Interest 223 152 188 543 453 562 450 428 Other Income 95 29 167 283 247 283 400 450 PBT 1,774 1,846 (3.9) 1,667 6.4 5,008 4,497 11.4 6,332 6,547 8,168 Less: Taxation 401 41 273 899 114 160 982 1,470 Less: Minority Interest (4) 1 (9) (11) 6 10 0 0 Recurring PAT 1,377 1,805 (23.7) 1,403 (1.9) 4,121 4,377 (5.9) 6,162 5,565 6,698 Exceptional items 0 0 129 129 0 0 0 0 Reported PAT 1,377 1,805 (23.7) 1,532 (10.1) 4,249 4,377 (2.9) 6,162 5,565 6,698 Gross Margin 74.0	3,974	3,680	3,270	2,727		2,032	2,096	(0.7)	705	0.8	695	700	Depreciation
Other Income 95 29 167 283 247 283 400 450 PBT 1,774 1,846 (3.9) 1,667 6.4 5,008 4,497 11.4 6,332 6,547 8,168 Less: Taxation 401 41 273 899 114 160 982 1,470 Less: Minority Interest (4) 1 (9) (11) 6 10 0 0 Recurring PAT 1,377 1,805 (23.7) 1,403 (1.9) 4,121 4,377 (5.9) 6,162 5,565 6,698 Exceptional items 0 0 129 129 0 0 0 0 Reported PAT 1,377 1,805 (23.7) 1,532 (10.1) 4,249 4,377 (2.9) 6,162 5,565 6,698 Key Ratios (%)	10,806	8,146	6,597	6,611	12.0	4,702	5,267	12.7	1,688	(3.4)	1,969	1,902	EBIT
PBT 1,774 1,846 (3.9) 1,667 6.4 5,008 4,497 11.4 6,332 6,547 8,168 Less: Taxation 401 41 273 899 114 160 982 1,470 Less: Minority Interest (4) 1 (9) (11) 6 10 0 0 Recurring PAT 1,377 1,805 (23.7) 1,403 (1.9) 4,121 4,377 (5.9) 6,162 5,565 6,698 Exceptional items 0 0 129 129 0 0 0 0 Reported PAT 1,377 1,805 (23.7) 1,532 (10.1) 4,249 4,377 (2.9) 6,162 5,565 6,698 Key Ratios (%) ////////////////////////////////////	406	428	450	562		453	543		188		152	223	Interest
Less: Taxation401412738991141609821,470Less: Minority Interest(4)1(9)(11)61000Recurring PAT1,3771,805(23.7)1,403(1.9)4,1214,377(5.9)6,1625,5656,698Exceptional items001291290000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	450	450	400	283		247	283		167		29	95	Other Income
Less: Minority Interest (4) 1 (9) (11) 6 10 0 0 Recurring PAT 1,377 1,805 (23.7) 1,403 (1.9) 4,121 4,377 (5.9) 6,162 5,565 6,698 Exceptional items 0 0 129 129 0 0 0 0 Reported PAT 1,377 1,805 (23.7) 1,532 (10.1) 4,249 4,377 (2.9) 6,162 5,565 6,698 Key Ratios (%) 5 71.7 1,805 (23.7) 1,532 (10.1) 4,249 4,377 (2.9) 6,162 5,565 6,698 Key Ratios (%) 5 71.7 1,805 72.5 72.0 73.0 EBITDA Margin 15.4 16.3 (96) 14.5 85 15.0 14.3 73 15.0 15.0 16.2 Tax / PBT 22.6 2.2 16.4 17.9 2.5 2.5	10,850	8,168	6,547	6,332	11.4	4,497	5,008	6.4	1,667	(3.9)	1,846	1,774	PBT
Recurring PAT1,3771,805(23.7)1,403(1.9)4,1214,377(5.9)6,1625,5656,698Exceptional items001291290000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	1,953	1,470	982	160		114	899		273		41	401	Less: Taxation
Exceptional items00129129000Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	0	0	0	10		6	(11)		(9)		1	(4)	Less: Minority Interest
Reported PAT1,3771,805(23.7)1,532(10.1)4,2494,377(2.9)6,1625,5656,698Key Ratios (%)Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	8,897	6,698	5,565	6,162	(5.9)	4,377	4,121	(1.9)	1,403	(23.7)	1,805	1,377	Recurring PAT
Key Ratios (%) 74.0 71.7 229 74.0 7 74.2 71.7 259 72.5 72.0 73.0 EBITDA Margin 15.4 16.3 (96) 14.5 85 15.0 14.3 73 15.0 15.0 16.2 Tax / PBT 22.6 2.2 16.4 17.9 2.5 2.5 15.0 18.0	0		0	0		0	129		129		0	0	Exceptional items
Gross Margin74.071.722974.0774.271.725972.572.073.0EBITDA Margin15.416.3(96)14.58515.014.37315.015.016.2Tax / PBT22.62.216.417.92.52.515.018.0	8,897	6,698	5,565	6,162	(2.9)	4,377	4,249	(10.1)	1,532	(23.7)	1,805	1,377	Reported PAT
EBITDA Margin 15.4 16.3 (96) 14.5 85 15.0 14.3 73 15.0 15.0 16.2 Tax / PBT 22.6 2.2 16.4 17.9 2.5 2.5 15.0 18.0													Key Ratios (%)
Tax / PBT 22.6 2.2 16.4 17.9 2.5 2.5 15.0 18.0	73.5	73.0	72.0	72.5	259	71.7	74.2	7	74.0	229	71.7	74.0	Gross Margin
	18.4	16.2	15.0	15.0	73	14.3	15.0	85	14.5	(96)	16.3	15.4	EBITDA Margin
NPM 8.1 11.1 8.5 (38) 8.4 9.3 9.9 8.5 9.2	18.0	18.0	15.0	2.5		2.5	17.9		16.4		2.2	22.6	Tax / PBT
	11.1	9.2	8.5	9.9		9.3	8.4	(38)	8.5		11.1	8.1	NPM
EPS 7.0 9.2 (23.7) 7.2 (2.4) 21.0 22.3 (5.9) 31.4 28.3 34.1	45.3	34.1	28.3	31.4	(5.9)	22.3	21.0	(2.4)	7.2	(23.7)	9.2	7.0	EPS

Source: Company, BOBCAPS Research

Fig 2 – Segmental revenue

(Rs mn)	Q3FY25	Q3FY24	YoY (%)	Q2FY25	QoQ (%)	9MFY25	9MFY24	YoY (%)	FY24	FY25E	FY26E	FY27E
Formulations	14,340	13,420	6.9	13,740	4.4	41,120	37,950	8.4	49,825	55,021	61,299	67,516
India	6,140	5,960	3.0	6,090	0.8	17,950	16,970	5.8	22,000	24,305	26,834	29,415
US	5,210	4,740	9.9	4,670	11.6	14,490	13,080	10.8	17,300	19,138	21,151	23,189
ROW	2,990	2,720	9.9	2,980	0.3	8,680	7,900	9.9	10,525	11,578	13,314	14,912
API	2,590	2,890	(10.4)	2,740	(5.5)	7,920	9,160	(13.5)	12,465	10,595	11,655	12,820
Net Sales	16,930	16,310	3.8	16,481	2.7	49,040	47,110	4.1	62,290	65,616	72,954	80,336

Source: Company, BOBCAPS Research









Fig 5 – EBITDA Margin increased due to better growth in






Source: Company, BOBCAPS Research

Fig 7 – Domestic growth lowered due to higher Azithromycin base



Source: Company, BOBCAPS Research

Fig 4 – EBITDA growth declined due to lower product mix



Source: Company, BOBCAPS Research





Fig 6 – PAT growth lowered due to higher ETR





Source: Company, BOBCAPS Research



Valuation methodology

ALPM's numbers were below our estimates due to India sales being affected by lower acute sales industry-wide and higher base of Azithromycin, followed by lower US and API sales affected by price erosion pressure. We continue to believe the worst is over for the company as new product launches in the US will likely offset price erosion pressure (only 50% of new products are in oral solids), while India sales are expected to bounce back as Azithromycin sales have normalised followed by API sales recovery from H2FY25E. Due to recovery in domestic and API sales, we expect ALPM's sales/earnings to grow at CAGRs of 11%/26% over FY25E-27E.

As earnings were lower than our estimates by 20% in Q3FY25, we cut our EPS estimates for FY25 by 17% to Rs 28.3, for FY26 by 20% to Rs 34.1 and for FY27 by 18% to Rs 45. However, given growth in the normalised base of Azithromycin, healthy traction in the Animal Health and Specialised businesses and strong non-oral solid portfolio in the US region, we maintain our BUY rating and value the stock at 28x Dec'26 EPS to yield a TP of Rs 1,032 (Rs 1,412 earlier).

(Po mn)	Actual New			Old			Change (%)			
(Rs mn)	FY24	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Sales	62,290	65,616	72,954	80,336	68,890	76,575	84,338	(4.8)	(4.7)	(4.7)
EBITDA	9,337	9,867	11,825	14,780	11,213	13,904	17,097	(12.0)	(14.9)	(13.6)
EBITDA margin (%)	15.0	15.0	16.2	18.4	16.3	18.2	20.3	(124bps)	(195bps)	(187bps)
EPS (Rs)	31	28	34	45	34.1	42.7	54.9	(17.0)	(20.2)	(17.6)

Fig 9 – Revised estimates

Source: Company, BOBCAPS Research

Fig 10 – Key assumption

(Rs mn)	FY24	FY25E	FY26E	FY27E
Revenue	62,290	65,616	72,954	80,336
EBITDA	9,337	9,867	11,825	14,780
PAT	6,172	5,565	6,698	8,897
EPS (Rs)	31.4	28.3	34.1	45.3
EBITDA Margin (%)	15.0	15.0	16.2	18.4
PAT Margin (%)	9.9	8.5	9.2	11.1

Source: Company, BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- adverse action on manufacturing facilities catering to the US,
- slow pace of new approvals/launches, and
- escalation in raw material prices or disruption in supply.



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	56,526	62,290	65,616	72,954	80,336
EBITDA	7,083	9,337	9,867	11,825	14,780
Depreciation	2,754	2,727	3,270	3,680	3,974
EBIT	4,329	6,611	6,597	8,146	10,806
Net interest inc./(exp.)	(502)	(562)	(450)	(428)	(406)
Other inc./(exp.)	27	283	400	450	450
Exceptional items	0	0	0	0	0
EBT	3,855	6,332	6,547	8,168	10,850
Income taxes	126	160	982	1,470	1,953
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	3,729	6,172	5,565	6,698	8,897
Adjustments	0	0	0	0	0
Adjusted net profit	3,729	6,172	5,565	6,698	8,897

Balance Sheet

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Accounts payables	6,798	7,356	8,090	8,994	9,904
Other current liabilities	2,343	2,038	3,281	3,648	3,936
Provisions	1,763	1,748	1,841	2,047	2,254
Debt funds	7,220	5,132	4,875	4,631	4,400
Other liabilities	0	0	0	0	0
Equity capital	393	393	393	393	393
Reserves & surplus	42,082	46,093	49,495	54,031	60,766
Shareholders' fund	42,475	46,486	49,888	54,424	61,159
Total liab. and equities	60,598	62,759	67,975	73,744	81,653
Cash and cash eq.	823	1,266	5,372	4,057	3,639
Accounts receivables	10,464	10,248	10,786	14,991	23,110
Inventories	14,753	16,435	17,977	20,987	21,350
Other current assets	3,598	3,169	1,968	2,189	2,410
Investments	963	930	930	930	930
Net fixed assets	23,985	25,467	25,697	25,348	24,970
CWIP	6,013	5,244	5,244	5,244	5,244
Intangible assets	0	0	0	0	0
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	60,598	62,759	67,975	73,744	81,653

Cash Flows

Casili i lows					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	5,352	8,651	10,475	4,848	5,979
Capital expenditures	(8,665)	(3,450)	(3,500)	(3,330)	(3,596)
Change in investments	221	33	0	0	0
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(8,445)	(3,417)	(3,500)	(3,330)	(3,596)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	49	(2,089)	(257)	(244)	(232)
Interest expenses	(502)	(562)	(450)	(428)	(406)
Dividends paid	(1,966)	(2,162)	(2,162)	(2,162)	(2,162)
Other financing cash flows	5,639	21	0	0	0
Cash flow from financing	3,221	(4,792)	(2,869)	(2,834)	(2,800)
Chg in cash & cash eq.	128	443	4,106	(1,315)	(417)
Closing cash & cash eq.	823	1,266	5,372	4,057	3,639

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27E
Reported EPS	17.4	31.4	28.3	34.1	45.3
Adjusted EPS	17.4	31.4	28.3	34.1	45.3
Dividend per share	10.0	11.0	11.0	11.0	11.0
Book value per share	216.1	236.5	253.8	276.9	311.2
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27E
EV/Sales	3.1	2.8	2.7	2.4	2.1
EV/EBITDA	24.9	19.0	17.8	14.6	11.5
Adjusted P/E	49.9	27.7	30.7	25.5	19.2
P/BV	4.0	3.7	3.4	3.1	2.8
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27E
Tax burden (Net profit/PBT)	96.7	97.5	85.0	82.0	82.0
Interest burden (PBT/EBIT)	89.0	95.8	99.2	100.3	100.4
EBIT margin (EBIT/Revenue)	7.7	10.6	10.1	11.2	13.5
Asset turnover (Rev./Avg TA)	25.9	30.7	30.8	32.0	32.2
Leverage (Avg TA/Avg Equity)	1.2	1.1	1.1	1.1	1.1
Adjusted ROAE	7.2	13.9	11.5	12.8	15.4
Ratio Analysis					
Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27E
YoY growth (%)					
Revenue	6.5	10.2	5.3	11.2	10.1
EBITDA	(19.0)	31.8	5.7	19.9	25.0
	(34.4)	80.2	(9.7)	20.4	32.8
Adjusted EPS	(34.4)				
Adjusted EPS Profitability & Return ratios (%	()				
,	()	15.0	15.0	16.2	18.4
Profitability & Return ratios (%)		15.0 10.1	16.2 11.2	18.4 13.5
Profitability & Return ratios (% EBITDA margin) 12.5	15.0			
Profitability & Return ratios (% EBITDA margin EBIT margin) 12.5 7.7	15.0 10.6	10.1	11.2	13.5

Aujusteu pront margin	0.0	9.9	0.5	9.Z	11.1
Adjusted ROAE	7.2	13.9	11.5	12.8	15.4
ROCE	8.0	13.6	13.2	15.1	18.1
Working capital days (days)					
Receivables	68	60	60	75	105
Inventory	95	96	100	105	97
Payables	44	43	45	45	45
Ratios (x)					
Gross asset turnover	1.6	1.6	1.6	1.6	1.7
Current ratio	2.7	2.8	2.7	2.9	3.1
Net interest coverage ratio	8.6	11.8	14.7	19.0	26.6
Adjusted debt/equity	0.2	0.1	0.0	0.0	0.0

Adjusted debt/equity 0.2 0.1 Source: Company, BOBCAPS Research | Note: TA = Total Assets

ALEMBIC PHARMA



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ALEMBIC PHARMA (ALPM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

ALEMBIC PHARMA



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.